Drug
Mazdutide clinical trials
Also written IBI362 and LY3305677.
- studies test it
- 40
- open now
- 16
- in phase 3
- 10
- first study started
- 2016
Keep track of what changes. Save the mazdutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2026 (12)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 8 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 12
- Phase 3
- 10
- Phase 4
- 5
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 13
Innovent Biologics (Suzhou) Co. Ltd. (20) · Eli Lilly and Company (7) · Shanghai Zhongshan Hospital (2) · Tongji Hospital (2) · Hongwei Jiang (1) · The Second Affiliated Hospital of Chongqing Medical University (1) · Huijie Zhang (1) · Yanbing Li (1)
Often tested with
Tested in the same studies.
Dulaglutide (1) · Metformin (1) · Digoxin (1) · Warfarin (1) · Atorvastatin (1) · Finerenone (1) · Eloralintide (1) · Tirzepatide (1)
Studies
Open first, then newest update. How each study uses mazdutide is read from its arms, and is right about nine times in ten.
Testing it · 40
- ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementRecruitingNot applicableShanghai Zhongshan HospitalNCT07517042Written as Mazdutide
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityRecruitingPhase 4China National Center for Cardiovascular DiseasesNCT07657676Written as Mazdutide
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Written as LY3305677
- Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)RecruitingPhase 4West China HospitalNCT07718126Written as Mazdutide
- Efficacy of Mazdutide on Fatty PancreasNot yet recruitingNot applicableTongji HospitalNCT07803705Written as mazdutide
- Mazdutide for Weight Management and Gout in Adults With ObesityNot yet recruitingPhase 4Hongwei JiangNCT07824895Written as Mazdutide
- Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)RecruitingPhase 3The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07083154Written as Mazdutide
- Body-weight Reduction Effect on Portal Hypertension in Compensated CirrhosisNot yet recruitingNot applicableThe Second Affiliated Hospital of Chongqing Medical UniversityNCT07797101Written as Mazdutide injection
- Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial CancerNot yet recruitingPhase 2Tongji HospitalNCT07781150Written as Mazdutide(Dual GLP-1R/GCGR Agonist)
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNot yet recruitingPhase 4Huijie ZhangNCT07775846Written as Mazdutide
- Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled TrialNot yet recruitingNot applicableYanbing LiNCT07767552Written as Mazdutide
- Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNot yet recruitingNot applicableTianjin Medical UniversityNCT07713992Written as Mazdutide(Dual GLP-1R/GCGR Agonist)
- Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)Not yet recruitingPhase 4Shandong Provincial HospitalNCT07654062Written as Mazdutide
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07469800Written as IBI362
- A Study of IBI362 in Chinese Adolescents With Obesity or OverweightRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07255209Written as IBI362
- A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06931028Written as IBI362
- A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Active, not recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT06937749Written as IBI362
- A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityActive, not recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT06862908Written as IBI362
- Efficacy of Mazdutide for Treating PCOSCompletedPhase 1/2Shanghai Zhongshan HospitalNCT06519656Written as Mazdutide
- A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderCompletedPhase 2Eli Lilly and CompanyNCT06817356Written as Mazdutide
See all 40 studies that test mazdutide →
As the comparator · 2 — what is tested is compared with mazdutide
- A Study of HRS-4729 Injection in Participants With Type 2 DiabetesNot yet recruitingPhase 2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07843862Written as Mazdutide
- A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorNot yet recruitingPhase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07417306Written as Mazdutide
Codes
What other systems call mazdutide · ClinicalTrials.gg INT001730
- MeSH (NLM) C000719829mazdutideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) MB76Z4IBZ5MAZDUTIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q123248554mazdutideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C186406MazdutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719829 | mazdutide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | MB76Z4IBZ5 | MAZDUTIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123248554 | mazdutide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C186406 | Mazdutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.